Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Ciscom Corp. Strengthens Its Board of Directors with Addition of Two Experienced Industry Leaders (click to learn more) Silver North Options GDR Silver Project, Silvertip-Midway District, Yukon (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lineage Cell Therapeutics Inc LCTX

Healthcare Biotechnology
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs. The Company’s programs are based on its cell-based technology platform and associated development and manufacturing capabilities. From this platform, the Company designs, develops, manufactures, and tests specialized human cells with anatomical and... see more

Recent & Breaking News (NYSEAM:LCTX)

LifeMap Sciences, a Subsidiary of BioTime, Reports Its Databases Currently Utilized by an Estimated Two Million Unique Visitors Annually according to Google Analytics

Business Wire February 11, 2013

BioTime's Subsidiary OncoCyte Corporation Provides an Update on the Development of the Novel Pan-Cancer Diagnostic Product PanC-DxTM

Business Wire January 31, 2013

LifeMap Sciences, a Subsidiary of BioTime, Announces Publication of Research Report Describing Non-Redundant Compendium of Human Non-Coding RNA Authored by GeneCards® Scientists

Business Wire January 30, 2013

Record Levels of Available Cash and Moderate R&D Development Will See Big Pharma M&A Activity Increase in 2013

Marketwired January 28, 2013

Key to Success, How to Profit: BTX, INTC and CPLP

Marketwired January 23, 2013

BioTime CEO Dr. Michael West to Present at Scale-Up and Manufacturing of Cell-Based Therapies II Conference

Business Wire January 18, 2013

The Real Story Behind TCX, BTX, NSU and TA

Marketwired January 16, 2013

BioTime Submits Protocol for Initiation of Human Clinical Trials of Renevia(tm) in Europe

Business Wire January 10, 2013

LifeMap Sciences, a Subsidiary of BioTime, Inc., Announces the Release of MalaCards Version 1.02

Business Wire January 9, 2013

Perfect Trade Setups, How to Play BSX, NBY, BTX and PFE

Marketwired January 9, 2013

BioTime Signs Definitive Agreement With Geron Regarding Stem Cell Assets

Business Wire January 7, 2013

BioTime Announces the Appointment of Jeffrey Janus as Vice President

Business Wire December 20, 2012